Literature DB >> 8564982

Antiproliferative responses to two human colon cancer cell lines to vitamin D3 are differently modified by 9-cis-retinoic acid.

K F Kane1, M J Langman, G R Williams.   

Abstract

1 alpha,25-Dihydroxyvitamin D3 [1,25(OH)2D3] exerts antiproliferative actions in colorectal cancer, but their underlying molecular mechanisms have not been determined. 1,25(OH)2D3 regulates target gene transcription via a specific nuclear vitamin D receptor (VDR), which mediates hormone action preferentially as a heterodimer with 9-cis-retinoic acid receptors (RXRs). We investigated the actions of 1,25(OH)2D3 and 9-cis-retinoic acid (RA) in two human colon cancer cell lines, HT-29 and Caco-2. Both expressed mRNAs encoding VDR, RXR alpha, and RXR gamma, and VDR was regulated posttranscriptionally in Caco-2 cells. There was an antiproliferative response of both cell lines to 1,25(OH)2D3. 9-cis-RA exerted antiproliferative effects on Caco-2 cells but blocked 1,25(OH)2D3 actions in HT-29 cells. The 1,25(OH)2D3-responsive gene 25-hydroxyvitamin D3 24-hydroxylase was induced in both cell lines b 1,25(OH)2D3 but in only HT-29 cells by 9-cis-RA. 1,25(OH)2D3 and 9-cis-RA cotreatment enhanced 24-hydroxylase expression in HT-29 cells only. The 24-hydroxylase enzyme is known to result in catabolism of 1,25(OH)2D3 and attenuation of its actions. Increased 24-hydroxylase activity in HT-29 cells, but not in Caco-2 cells, in response to 9-cis-RA may account for some of the complex cell-specific responses demonstrated in these studies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8564982

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Slug expression inhibits calcitriol-mediated sensitivity to radiation in colorectal cancer.

Authors:  Victoria J Findlay; R Eric Moretz; Cindy Wang; Silvia G Vaena; Savannah G Bandurraga; Michael Ashenafi; David T Marshall; Dennis K Watson; E Ramsay Camp
Journal:  Mol Carcinog       Date:  2013-08-31       Impact factor: 4.784

2.  Regulation of VDR Expression in Apc-Mutant Mice, Human Colon Cancers and Adenomas.

Authors:  Charles Giardina; Masako Nakanishi; Awaad Khan; Anton Kuratnik; Wanli Xu; Bruce Brenner; Daniel W Rosenberg
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-14

3.  Importance of apical membrane delivery of 1,25-dihydroxyvitamin D3 to vitamin D-responsive gene expression in the colon.

Authors:  Nicholas J Koszewski; Ronald L Horst; Jesse P Goff
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-07-26       Impact factor: 4.052

4.  Phosphorylation of Human Retinoid X Receptor α at Serine 260 Impairs Its Subcellular Localization, Receptor Interaction, Nuclear Mobility, and 1α,25-Dihydroxyvitamin D3-dependent DNA Binding in Ras-transformed Keratinocytes.

Authors:  Sylvester Jusu; John F Presley; Richard Kremer
Journal:  J Biol Chem       Date:  2016-11-16       Impact factor: 5.157

Review 5.  Vitamin D resistance and colon cancer prevention.

Authors:  Charles Giardina; James P Madigan; Cassandra A Godman Tierney; Bruce M Brenner; Daniel W Rosenberg
Journal:  Carcinogenesis       Date:  2011-12-16       Impact factor: 4.944

6.  Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the likelihood of colon adenoma recurrence.

Authors:  Jan B Egan; Patricia A Thompson; Erin L Ashbeck; David V Conti; David Duggan; Elizabeth Hibler; Peter W Jurutka; Elizabeth C Leroy; María Elena Martínez; David Mount; Elizabeth T Jacobs
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

7.  Induction of retinoic acid receptor beta mediates growth inhibition in retinoid resistant human colon carcinoma cells.

Authors:  B Nicke; E O Riecken; S Rosewicz
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

Review 8.  Chemoprevention of colorectal cancer.

Authors:  M Langman; P Boyle
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

9.  Retinoic acid enhances the gene expression of human polymeric immunoglobulin receptor (pIgR) by TNF-alpha.

Authors:  N Takenouchi-Ohkubo; M Asano; H Chihaya; W U Chung-Hsuing; K Ishikasa; I Moro
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

10.  A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors.

Authors:  Josephia R Muindi; Candace S Johnson; Donald L Trump; Renee Christy; Kristie L Engler; Marwan G Fakih
Journal:  Cancer Chemother Pharmacol       Date:  2009-04-26       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.